Article Text

other Versions

PDF
Statin therapy in lupus-mediated atherogenesis: two birds with one stone?
  1. Sander I van Leuven1,2,3,
  2. Yanice V Mendez-Fernandez1,
  3. Erik S Stroes2,
  4. Paul P Tak3,
  5. Amy S Major1
  1. 1Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
  2. 2Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
  3. 3Department of Clinical Immunology and Rheumatology, Academic Medical Center, Amsterdam, The Netherlands
  1. Correspondence to Sander I van Leuven, Academic Medical Center, Department of Vascular Medicine, Room F4-159.2, Meibergdreef 9, 1100 DD Amsterdam, The Netherlands; s.i.vanleuven{at}amc.uva.nl

Abstract

The atherosclerotic process is accelerated in patients with systemic lupus erythematosus (SLE). In addition to a robust lipid-lowering effect, various immunomodulatory functions have been ascribed to statins. By virtue of the latter they may be able to reduce atherosclerotic vascular disease in SLE by inhibiting immune activation within the arterial wall and by attenuating lupus activity. The effects of statins on SLE as well as on lupus-mediated atherogenesis in vivo are discussed in this viewpoint.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.